Back to search
FDAFDA · Food and drugs·Recall number D-1579-2019

Timolol- Dorzolamide- Latanoprost P-F (0.5/2.0/0.005%) ophthalmic drops, packaged in 5mL bottles, Rx only, ImprimisRx NJ 1705 Route 46 West, Suite 4, Ledgewood, NJ 07852 (844) 446-6979

Published August 7, 2019 · Recall initiated: July 17, 2019

Summary

FDA records drug Class II recall D-1579-2019, published August 7, 2019 and initiated July 17, 2019. Recalling firm: ImprimisRx NJ; Status: Terminated; Reported quantity: 246 bottles; Lot: Lot #: 03132019@2, Exp. 09/17/2019; 05102019@2, Exp. 11/02/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
ImprimisRx NJ
Distributor
Nationwide within the United States
Lot
Lot #: 03132019@2, Exp. 09/17/2019; 05102019@2, Exp. 11/02/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Timolol- Dorzolamide- Latanoprost P-F (0.5/2.0/0.005%) ophthalmic drops, packaged in 5mL bottles, Rx only, ImprimisRx NJ 1705 Route 46 West, Suite 4, Ledgewood, NJ 07852 (844) 446-6979 recalled?

Yes. FDA published recall D-1579-2019 on August 7, 2019. Reported hazard: Subpotent Drug

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit